Parisa Shamsesfandabadi | Radiation Oncology | Best Researcher Award

Posted on by sciencefather

Dr. Parisa Shamsesfandabadi | Radiation Oncology | Best Researcher Award

PGY5 Resident, Allegheny Health Network, United States 🧬

Dr. Parisa Shamsesfandabadi 🇺🇸 is a dedicated physician and radiation oncology resident with an exceptional academic and research portfolio. Currently serving as Chief Resident at Allegheny Health Network in Pittsburgh, PA, she is recognized for her contributions to oncology, her innovative research presentations, and her commitment to advancing cancer treatment technologies. With a U.S. citizenship and a background rooted in both Iranian and American institutions, Dr. Shamsesfandabadi exemplifies global excellence in medicine, research, and leadership. 🌎👩‍⚕️✨

Profile

Orcid

🎓 Education

Dr. Shamsesfandabadi earned her medical degree from Kashan University of Medical Sciences and Health Services (KaUMS), Iran. She completed her Transitional Year internship at Southern Hills Hospital, Las Vegas, NV, and began her residency in Radiation Oncology at Allegheny Health Network, Pittsburgh, PA, where she now serves as Chief Resident. Her academic journey began at the prestigious Tehran Farzanegan School under NODET (National Organization for Development of Exceptional Talents), showcasing her lifelong pursuit of excellence. 📚🎓

👩‍🔬 Experience

Dr. Shamsesfandabadi brings a rich blend of clinical, academic, and research experiences. She has served in various positions including Research Associate at the VA Medical Center in Durham, NC, and Visiting Scholar at institutions such as Duke University and UNC Chapel Hill. Her hands-on roles span across radiotherapy, imaging, oncology, and pediatric care, with responsibilities ranging from clinical assistantship to advanced cancer imaging analysis. Her involvement in key committees like the CARROS Quality & Safety Committee and editorial roles with Red Journal and eContour reflect her leadership. 🏥📊

🔬 Research Interest

Her research focuses primarily on radiation oncology innovations, image-guided therapies, prostate and breast cancer treatments, and MR-Linac technologies. She also explores cost-effectiveness in cancer treatment, radiogenomics, and functional imaging. Her contributions have impacted multidisciplinary cancer management, showcasing her dedication to precision medicine and patient-centered care. 🧠🩻💡

🏆 Awards

Dr. Shamsesfandabadi has earned numerous awards and recognitions including the 2023 $25,000 Claude Worthington Benedum Foundation Grant for MR-Linac Sarcoma research. She is a recipient of multiple travel and abstract awards from leading organizations such as ASTRO, ESTRO, ACRO, ABS, and the American Radium Society. Her consistent academic excellence has been acknowledged since her school days, earning gold medals, Olympiad titles, and national recognition for her scientific talent. 🥇📜🏅

📚 Publications

Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma (HCC) with SPECT Functional Treatment Planning – Advances in Radiation Oncology, 2023 (Accepted)

Comparison of Collapsed Cone and Monte Carlo Algorithms in Tangential Breast Planning – Journal of Radiotherapy in Practice, April 2023

Radiogenomics of lower-grade glioma: tumor shape and genomics – Journal of Neuro-Oncology, May 2017 | Cited by 125+

Radiogenomic analysis of lower-grade glioma – SPIE Proceedings, March 2017

Comparison of Regular and Probiotic Yogurts in Treatment of Acute Watery Diarrhea in Children – Journal of Probiotics and Health, Feb 2016

🏁 Conclusion

Dr. Parisa Shamsesfandabadi is a highly competitive candidate for the Best Researcher Award. Her academic pedigree, wide-ranging research interests, early career recognitions, and commitment to clinical innovation in radiation oncology make her a standout contender. With continuous growth in independent research and authorship, she is poised to become a leading figure in her field.

 

Dr. Muhammad Kibriya | Cancer molecular genomics | Best Researcher Award

Posted on by sciencefather

Dr. Muhammad Kibriya | Cancer molecular genomics | Best Researcher Award

Dr. Muhammad Kibriya, University of Chicago, United States

Dr. Muhammad G. Kibriya is a Research Associate Professor at the Institute for Population and Precision Health, University of Chicago. He holds an MBBS from Dhaka University (1987) and a PhD in Medicine from the Medical Academy Sofia, Bulgaria (1994). With expertise in nephrology, diabetology, epidemiology, and cancer genomics, his research focuses on molecular genomics, gene-environment interactions, and oncogenesis. Dr. Kibriya has co-led large-scale studies like HEALS, BEST, and COMPASS. He pioneered a novel Luminex-based assay for telomere length measurement and has extensive experience in cutting-edge genomic technologies. 📊🧬

Publication Profile

Orcid

Academic Background

Dr. Muhammad G. Kibriya earned his MBBS from the Institute for Postgraduate Medicine & Research, Dhaka University in 1987, followed by a PhD in Medicine from the Medical Academy Sofia, Bulgaria, in 1994. His multidisciplinary training spans medicine, nephrology, diabetology, epidemiology, environmental health, and cancer genomics, showcasing his comprehensive academic foundation for impactful research.

Research Interests

Dr. Kibriya’s research focuses on integrative molecular genomics and gene-environment interactions in cancer epidemiology. His work addresses critical areas such as oncogenesis and its applications in disease classification, therapeutic response, and prognosis across various cancers, including colorectal, breast, thyroid, and non-melanoma skin cancers. These interests align with global priorities in precision health and public health sciences.

Technical Expertise

Dr. Kibriya has extensive experience in advanced molecular genomics assays. These include genome-wide methylation, metagenomics, microbiome assays, high-throughput genome-wide genotyping, gene expression, and next-generation sequencing. His novel development of a non-PCR-based high-throughput assay for measuring relative telomere length demonstrates innovative thinking and technological advancement.

Research Focus

Dr. Muhammad G. Kibriya focuses on gene-environment interactions, particularly the molecular mechanisms underlying cancer and chronic diseases. His research spans non-melanoma skin cancer (NMSC), colorectal carcinoma, thyroid cancer, and the impacts of environmental exposures like arsenic and metal mixtures on epigenetics and transcriptomic profiles. He explores genetic mutations, DNA methylation, telomere dynamics, and inflammation-related pathways in cancer development and progression. Dr. Kibriya’s work integrates high-throughput sequencing, molecular profiling, and innovative assay development to address critical gaps in cancer therapy and environmental health. 🧬🌱🩺💡

Publication Top Notes

  • Gene–Environment Interaction: Small Deletions (DELs) and Transcriptomic Profiles in NMSC
    Cells, 2025 | DOI: 10.3390/cells14020095 
  • Exposure to Metal Mixtures and Telomere Length in Bangladeshi Children
    American Journal of Epidemiology, 2025 | DOI: 10.1093/aje/kwae181 
  • Assessment of Multipollutant Exposures Using Silicone Wristbands Among Bangladeshi Youth
    IJERPH, 2024 | DOI: 10.3390/ijerph21121691 
  • Association of KRAS Mutation and Gene Pathways in Colorectal Carcinoma
    IJMS, 2024 | DOI: 10.3390/ijms25158094 
  • Molecular Profiling in NMSC in a Population Exposed to Arsenic
    Cells, 2024 | DOI: 10.3390/cells13121056 
  • Association of Microsatellite Instability in Colorectal Carcinoma
    Medicina, 2024 | DOI: 10.3390/medicina60030348 
  • Air Pollution Exposure and Cardiometabolic Biomarkers
    Environmental Research, 2024 | DOI: 10.1016/j.envres.2023.117496 
  • Pathways Related to Colon Inflammation and Colorectal Carcinoma
    Cancers, 2023 | DOI: 10.3390/cancers15112921 
  • DNA Promoter Methylation and BRAF Mutation in Thyroid Cancer
    Current Oncology, 2023 | DOI: 10.3390/curroncol30030227 
  • DNA Methylation QTL Mapping Across Human Tissues
    Nature Genetics, 2023 | DOI: 10.1038/s41588-022-01248-z 
  • Fine-Mapping the 10q24.32 Arsenic Metabolism Efficiency Locus
    PLOS Genetics, 2023 | DOI: 10.1371/journal.pgen.1010588 
  • Comparing Tissues of Early and Late Onset Colorectal Carcinoma
    IJMS, 2022 | DOI: 10.3390/ijms232214261 
  • Arsenic Exposure and Transcriptomic Profile in Basal Cell Carcinoma
    Cancers, 2022 | DOI: 10.3390/cancers14225598 
  • Spatial Accessibility of Primary Care and Hypertension Control
    Circulation, 2022 | DOI: 10.1161/CIRCOUTCOMES.121.008845 
  • Relative Telomere Length in Colorectal Carcinoma
    Cancers, 2022 | DOI: 10.3390/cancers14092250 

 

 

 

 

 

Mohamed Eltokhy | Cancer Biology | Best Researcher Award

Posted on by sciencefather

Mr. Mohamed Eltokhy | Cancer Biology | Best Researcher Award

MSc, TTUHSC, United States

Mohamed Ashraf Eltokhy is a dedicated researcher and Assistant Lecturer at Texas Tech University Health Science Center (TTUHSC) in Abilene, Texas, where he’s contributing to the development of innovative cancer therapies. With an academic background in pharmaceutical sciences, he has experience in both clinical and academic settings, focusing on immunotherapeutic and biotechnological approaches to cancer treatment. Passionate about improving cancer therapies, he leads impactful research initiatives, aiming to advance safer, more effective treatment options for patients.

Profile

Orcid

Google Scholar

Education 🎓

Mohamed holds a Bachelor’s degree in Pharmaceutical Science from Misr International University in Cairo, graduating with high honors (GPA 3.95). He further pursued a Master of Science in Microbiology and Immunology at Al-Azhar University. Currently, he’s a PhD candidate at TTUHSC, studying in the Department of Immunotherapeutic and Biotechnology. His academic journey is marked by consistent excellence and a strong commitment to cancer research, achieving a cGPA of 3.948.

Experience 🧑‍🏫

Mohamed’s diverse experience spans research, academia, and leadership. As the CEO of Neopurpose Therapeutics, he drives strategic decisions, investor relations, and competitor analysis. In academia, he has held positions such as Assistant Lecturer at Misr International University, where he taught microbiology, immunology, and biochemistry. His research experience includes a guest researcher role at Leiden University and involvement in innovative cancer drug studies at TTUHSC, demonstrating his commitment to advancing scientific knowledge and application in cancer therapeutics.

Research Interest 🔬

Mohamed’s research focuses on developing novel anti-cancer agents and bioprinted tumor-on-chip models for drug discovery. His work includes in vitro screening of new compounds, mechanistic studies, and safety evaluations, as well as in vivo research to establish efficacy and safety. His overarching goal is to create more personalized cancer treatment options and to understand the molecular mechanisms involved in cancer progression and treatment.

Awards & Recognition 🏆

Throughout his career, Mohamed has received multiple awards, including the Texas Tech Accelerator Program Award in 2024, and a prestigious poster presentation at the American Association of Cancer Research (AACR). His excellence in academia was recognized with awards for valuable contributions at MIU’s senior conferences and honors for outstanding academic performance in Microbiology and Immunology.

Publications Top Notes 📑

  1. Dec 2021: Eltokhy, M. A., Saad, B. T., Eltayeb, W. N., Yahia, I. S., Aboshanab, K. M., & Ashour, M. S. E. “Exploring the Nature of the Antimicrobial Metabolites Produced by Paenibacillus ehimensis Soil Isolate MZ921932 Using a Metagenomic Nanopore Sequencing Coupled with LC-Mass Analysis,” Journal of Antibiotics (MDPI)..
  2. Nov 2021: Eltokhy, M. A., Saad, B. T., Eltayeb, W. N., El-Ansary, M. R., Aboshanab, K. M., & Ashour, M. S. E. “A metagenomic nanopore sequence analysis combined with conventional screening and spectroscopic methods for deciphering the antimicrobial metabolites produced by Alcaligenes faecalis soil isolate MZ921504,” Journal of Antibiotics (MDPI)..
  3. Sep 2020: Eassa, H. A., Eltokhy, M. A., Fayyaz, H. A., Khalifa, M. K. A., Shawky, S., Helal, N. A., & Nounou, M. I. “Current Topical Strategies for Skin-Aging and Inflammaging Treatment: Science versus Fiction,” Europe PMC..
  4. May 2019: Helal, N. A., Elnoweam, O., Eassa, H. A., Amer, A. M., Eltokhy, M. A., Helal, M. A., Fayyaz, H. A., & Nounou, M. I. “Integrated Continuous Manufacturing in Pharmaceutical Industry: Current Evolutionary Steps Towards Revolutionary Future,” Pharmaceutical Patent Analyst (Clarivate Analytics)..
  5. Jan 2019: Helal, N. A., Eassa, H. A., Amer, A. M., Eltokhy, M. A., Edafiogho, I., & Nounou, M. I. “Nutraceuticals’ novel formulations: the good, the bad, the unknown and patents involved,” Recent Patents on Drug Delivery & Formulation (Bentham Science)..